NCT07027124 2026-03-19
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
Clinical Trials
18 trialsNCT04104893 2026-02-27
CHOMP
VA Office of Research and Development
Phase 2 Active not recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT05766371 2025-12-30
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT04090528 2025-12-05
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT02312557 2025-12-03
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04471974 2025-07-22
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT04569461 2025-07-04
TALON
Duke University
Phase 2 Withdrawn
NCT02717156 2025-06-05
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
University of Southern California
Phase 2 Active not recruiting
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT04009967 2025-01-13
PICT-01
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT04116775 2022-06-23
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Portland VA Medical Center
Phase 2 Unknown
NCT03753243 2022-04-20
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Portland VA Medical Center
Phase 2 Recruiting
NCT04565496 2020-09-25
PEM-PRO
IRCCS San Raffaele
Phase 2 Unknown